# Ernexa (ERNA) — News

ERNA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/erna/news

## Recent headlines

- [Ernexa Therapeutics CEO Corner highlights appointment of Dr. Robert J. Spiegel as company sharpens oncology focus and advances ERNA-101 toward the clinic](https://www.ainvest.com/news/ernexa-therapeutics-ceo-corner-highlights-appointment-dr-robert-spiegel-company-sharpens-oncology-focus-advances-erna-101-clinic-2610) — AInvest Wire, Oct 1, 2026
  Ernexa Therapeutics (NASDAQ: ERNA) has announced the appointment of Dr. Robert J. Spiegel to its leadership team as the company continues to sharpen its focus on oncology and advance its lead cell therapy candidate, ERNA-101, toward clinical development. The move comes as the company prepares for a…
- [Ernexa Therapeutics appoints accomplished biopharmaceutical executive Robert J. Spiegel, M.D., FACP, to board of directors](https://www.ainvest.com/news/ernexa-therapeutics-appoints-accomplished-biopharmaceutical-executive-robert-spiegel-facp-board-directors-2609) — AInvest Wire, Sep 17, 2026
  Ernexa Therapeutics Inc. (NASDAQ: ENXA) has announced the appointment of Robert J. Spiegel, M.D., FACP, to its board of directors, effective immediately [1]. Dr. Spiegel brings over two decades of leadership experience in the biopharmaceutical industry, having previously held executive roles at…
- [Ernexa Therapeutics - Intends to broaden oncology program and advance next-generation IMSC candidates](https://www.ainvest.com/news/ernexa-therapeutics-intends-broaden-oncology-program-advance-generation-imsc-candidates-2609) — AInvest Wire, Sep 15, 2026
- [Ernexa Therapeutics - Clinical data from ERNA-101 proc study expected in Q4 2027](https://www.ainvest.com/news/ernexa-therapeutics-clinical-data-erna-101-proc-study-expected-q4-2027-2609) — AInvest Wire, Sep 15, 2026
  Ernexa Therapeutics (ERNX) announced that clinical data from its Phase II study of ERNA-101, a novel RNA-based therapeutic candidate, is expected to be released in the fourth quarter of 2027. The study, which is evaluating the safety, tolerability, and preliminary efficacy of ERNA-101 in patients…
- [Ernexa Therapeutics - Plans ERNA-101 ind submission in Q4 2026](https://www.ainvest.com/news/ernexa-therapeutics-plans-erna-101-ind-submission-q4-2026-2609) — AInvest Wire, Sep 15, 2026
  Ernexa Therapeutics (NASDAQ: ERNA) has outlined its plans to submit an Investigational New Drug (IND) application for its lead candidate, ERNA-101, in the fourth quarter of 2026, according to recent developments. The company has successfully completed process development for ERNA-101 and is now…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).